Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 4, 2013, Pages 485-493

  Herold, Betsy C ^a   Keller, Marla J ^a   Shi, Qiuhu ^b   Hoover, Donald R ^c   Carpenter, Colleen A ^a   Huber, Ashley ^a   Parikh, Urvi M ^d   Agnew, Kathy J ^e   Minkoff, Howard ^f   Colie, Christine ^g   Nowicki, Marek J ^h   D'Souza, Gypsyamber ⁱ   Watts, D Heather ^a,j   Anastos, Kathryn ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f MAIMONIDES MEDICAL CENTER   (United States)

^g GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^j EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

more..

Author keywords

Female genital tract; HIV; HSV; Inflammation; Mucosal immunity; WIHS

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ESCHERICHIA COLI; FEMALE; FEMALE GENITAL TRACT INFLAMMATION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; MUCOSAL IMMUNITY; PRIORITY JOURNAL; SMOKING; VAGINAL LAVAGE; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CERVIX UTERI; CHEMOKINES; CROSS-SECTIONAL STUDIES; CYTOKINES; ESCHERICHIA COLI; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; MUCOUS MEMBRANE; RNA, VIRAL; UTERINE CERVICITIS; VAGINA; VAGINAL DOUCHING; VAGINITIS; VIRAL LOAD; VIRUS SHEDDING;

EID: 84880206396     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182961cfc     Document Type: Article

References (52)

1. Bebell LM, Passmore JA, Williamson C, et al. Relationship between levels of inflammatory cytokines in the genital tract and CD4+ cell counts in women with acute HIV-1 infection. J Infect Dis. 2008;198:710-714.
2. Roberts L, Passmore JA, Mlisana K, et al. Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis. 2012;205:194-203.
3. Roberts L, Passmore JA, Williamson C, et al. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS. 2010;24:819-831.
4. Wang F, Graham WV, Wang Y, et al. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol. 2005;166:409-419.
5. Redd AD, Dabitao D, Bream JH, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci U S A. 2009;106:6718-6723.
6. Kwara A, Delong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis. 2008;46:719-725.
7. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001;358:1593-1601.
8. Kemal KS, Foley B, Burger H, et al. HIV-1 in genital tract and plasma of women:compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A. 2003;100:12972-12977.
9. Mitchell C, Hitti J, Paul K, et al. Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retroviruses. 2011;27:35-39.
10. Meier A, Alter G, Frahm N, et al. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol. 2007;81:8180-8191.
11. Shust GF, Cho S, Kim M, et al. Female genital tract secretions inhibit herpes simplex virus infection:correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol. 2010;63:110-119.
12. John M, Keller MJ, Fam EH, et al. Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis. 2005; 192:1731-1740.
13. Venkataraman N, Cole AL, Svoboda P, et al. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol. 2005;175:7560-7567.
14. Ghosh M, Fahey JV, Shen Z, et al. Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One. 2010;5:e11366.
15. Keller MJ, Guzman E, Hazrati E, et al. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS. 2007;21:467-476.
16. Keller MJ, Madan RP, Torres NM, et al. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One. 2011; 6:e16475.
17. Valore EV, Wiley DJ, Ganz T. Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infect Immun. 2006;74:5693-5702.
18. McNeely TB, Dealy M, Dripps DJ, et al. Secretory leukocyte protease inhibitor: AA human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest. 1995;96:456-464.
19. Keller MJ, Madan RP, Shust G, et al. Changes in the soluble mucosal immune environment during genital herpes outbreaks. J Acquir Immune Defic Syndr. 2012;61:194-202.
20. Madan RP, Carpenter C, Fiedler T, et al. Altered biomarkers of mucosal immunity and reduced vaginal Lactobacillus concentrations in sexually active female adolescents. PLoS One. 2012;7:e40415.
21. Ghartey JP, Carpenter C, Gialanella P, et al. Association of bactericidal activity of genital tract secretions with Escherichia coli colonization in pregnancy. Am J Obstet Gynecol. 2012;207:297.e1-e8.
22. Kalyousef S, Nieves E, Dinerman E, et al. Lactobacillus proteins are associated with the bactericidal activity against E. coli of female genital tract secretions. PLoS One. 2012;7:e49506.
23. Atashili J, Poole C, Ndumbe PM, et al. Bacterial vaginosis and HIV acquisition: A meta-analysis of published studies. AIDS. 2008;22:1493-1501.
24. Myer L, Denny L, Telerant R, et al. Bacterial vaginosis and susceptibility to HIV infection in South African women: A nested case-control study. J Infect Dis. 2005;192:1372-1380.
25. Cohen CR, Lingappa J.R. Baeten JM, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: A prospective cohort analysis among African couples. PLoS Med. 2012;9:e1001251.
26. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117-125.
27. Nugent RP, Krohn M.A. Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29:297-301.
28. Ma G, Greenwell-Wild T, Lei K, et al. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med. 2004;200:1337-1346.
29. Chang TL, Vargas J Jr, DelPortillo A, et al. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest. 2005;115:765-773.
30. Furci L, Sironi F, Tolazzi M, et al. Alpha-defensins block the early steps of HIV-1 infection:interference with the binding of gp120 to CD4. Blood. 2007;109:2928-2935.
31. Guo CJ, Tan N, Song L, et al. Alpha-defensins inhibit HIV infection of macrophages through upregulation of CC-chemokines. AIDS. 2004;18:1217-1218.
32. Mackewicz CE, Yuan J, Tran P, et al. alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS. 2003;17:F23-F32.
33. Zhang L, Yu W, He T, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science. 2002; 298:995-1000.
34. Kuhn L, Trabattoni D, Kankasa C, et al. Alpha-defensins in the prevention of HIV transmission among breastfed infants. J Acquir Immune Defic Syndr. 2005;39:138-142.
35. Farquhar C, VanCott TC, Mbori-Ngacha DA, et al. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis. 2002;186:1173-1176.
36. Pillay K, Coutsoudis A, Agadzi-Naqvi AK, et al. Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J Infect Dis. 2001;183:653-656.
37. Levinson P, Kaul R, Kimani J, et al. Levels of innate immune factors in genital fluids: Association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS. 2009;23:309-317.
38. Madan RP, Keller MJ, Herold BC. Prioritizing prevention of HIV and sexually transmitted infections:first-generation vaginal microbicides. Curr Opin Infect Dis. 2006;19:49-54.
39. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-uppressive factors produced by CD8+ T cells. Science. 1995;270:1811-1815.
40. Nazli A, Chan O, Dobson-Belaire WN, et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 2010;6:e1000852.
41. Mitchell CM, Balkus J, Agnew KJ, et al. Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines. AIDS Res Hum Retroviruses. 2008;24:667-671.
42. Ferreira VH, Nazli A, Khan G, et al. Endometrial epithelial cell responses to coinfecting viral and bacterial pathogens in the genital tract can activate the HIV-1 LTR in an NF{kappa}B-and AP-1-dependent manner. J Infect Dis. 2011;204:299-308.
43. Mhatre M, McAndrew T, Carpenter C, et al. Cervical intraepithelial neoplasia is associated with genital tract mucosal inflammation. Sex Transm Dis. 2012;39:591-597.
44. Mukura LR, Ghosh M, Fahey JV, et al. Genital tract viral load in HIV type 1-positive women correlates with specific cytokine levels in cervicalvaginal secretions but is not a determinant of Infectious virus or anti-HIV activity. AIDS Res Hum Retroviruses. 2012;28:1533-1539.
45. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis. 2012;205(suppl 3):S375-382.
46. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS. 2010;5:498-503.
47. Keating SM, Golub ET, Nowicki M, et al. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS. 2011;25:1823-1832.
48. Palella FJ Jr, Gange SJ, Benning L, et al. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS. 2010;24:1657-1665.
49. Wojna V, Robles L, Skolasky RL, et al. Associations of cigarette smoking with viral immune and cognitive function in human immunodeficiency virus-eropositive women. J Neurovirol. 2007;13:561-568.
50. Kabali C, Cheng DM, Brooks DR, et al. Recent cigarette smoking and HIV disease progression:no evidence of an association. AIDS Care. 2011;23:947-956.
51. Shuter J, Bernstein SL. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob Res. 2008;10:731-736.
52. Sha BE, Zariffard MR, Wang QJ, et al. Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis. 2005;191:25-32.